RT Journal Article
T1 Incidence and survival of rare cancers in the US and Europe.
A1 Botta, Laura
A1 Gatta, Gemma
A1 Trama, Annalisa
A1 Bernasconi, Alice
A1 Sharon, Elad
A1 Capocaccia, Riccardo
A1 Mariotto, Angela B
A1 RARECAREnet working group, 
K1 5 years net survival
K1 Europe
K1 USA
K1 differences
K1 incidence
K1 rare cancers
AB Geographical variability of cancer burden was almost exclusively estimated for common cancers. Since rare cancers (RC) have become an area of priority for basic and clinical research and public health organizations, this paper provides, using a common methodology, a detailed comparison of incidence and survival for RC in the US and Europe. We estimated incidence and net survival of 199 malignant RC from data of 2 580 000 patients collected by 18 US-SEER and 94 European registries, diagnosed within the most recent common period 2000-2007. RC were defined according to the criterion of crude annual incidence rates 65+ years of age. Use of standardized methods evidenced that incidence and survival rate of majority of RC were higher in the United States compared to Europe. Possible reasons for such differences, requiring further studies, include distribution of risk factors, ability to diagnose RC, different registration practices, and use of updated International Classification of Diseases for Oncology.
YR 2020
FD 2020-05-21
LK https://hdl.handle.net/10668/26639
UL https://hdl.handle.net/10668/26639
LA en
DS RISalud
RD Apr 9, 2025